KEGG   DRUG: Daratumumab and hyaluronidase
Entry
D11967            Mixture   Drug                                   
Name
Daratumumab and hyaluronidase;
Daratumumab (genetical recombination) and vorhyaluronidase alfa (genetical recombination);
Daratumumab and hyaluronidase-fihj;
Darzalex faspro (TN);
Darzquro (TN)
Product
DARZALEX FASPRO (Janssen Biotech)
Component
Daratumumab [DR:D10777], (Hyaluronidase [DR:D04456] | Hyaluronidase (human recombinant) [DR:D06604])
Remark
Therapeutic category: 4291
ATC code: L01FC01
Product: D11967<JP/US>
Efficacy
Antineoplastic
  Disease
Multiple myeloma [DS:H00010]
Light chain amyloidosis [DS:H02499]
  Type
Monoclonal antibody, combination
Comment
Treatment of light chain (AL) amyloidosis
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FC CD38 (Clusters of Differentiation 38) inhibitors
     L01FC01 Daratumumab
      D11967  Daratumumab and hyaluronidase <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Daratumumab/ Hyaluronidase
    D11967  Daratumumab and hyaluronidase
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D11967  Daratumumab and hyaluronidase
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11967
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system